Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K — Jul 29, 2026

$GLMDForm 6-KFiled Jul 29, 2026, 4:05 PM ET0001493152-26-035185Original filing

Galmed Pharmaceuticals' subsidiary has mutually agreed with Yissum Research Development Company of the Hebrew University of Jerusalem to terminate their license agreement effective July 31, 2026. The decision results in the reversion of all technology rights to Yissum and the cessation of funding for the associated patents, effectively ending the company's activities related to that licensed technology.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.